EXACT Therapeutics

Equities

EXTX

NO0010852213

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 15:45:00 16/05/2024 BST			5-day change	1st Jan Change
7.1 ^NOK	+1.43%		0.00%	-40.83%

04-19	EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study	MT

Exact Therapeutics as Reports Earnings Results for the Half Year Ended June 30, 2021

September 22, 2021 at 10:55 am

EXACT Therapeutics AS announced earnings results for the half year ended June 30, 2021. For the half year, the company announced operating loss was NOK 36.435 million compared to NOK 11.955 million a year ago. Net loss was NOK 36.201 million compared to NOK 11.308 million a year ago. Basic loss per share from continuing operations was NOK 1.21 compared to NOK 0.5 a year ago.

Latest news about EXACT Therapeutics

EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	04-18	CI
Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study	31/10/23	MT
EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2023	28/09/23	CI
EXACT Therapeutics AS Announces Appointment of Caspar Foghsgaard as SVP Commercial & Business Development Effective 1 November 2023	27/09/23	CI
Exact Therapeutics Jumps 13% After Positive Outcomes From Acoustic Cluster Therapy Trial	26/09/23	MT
EXACT Therapeutics Announces Positive Clinical Results from the Activate Phase I Dose Escalation	26/09/23	CI
Exact Therapeutics, Cordance Medical to Collaborate on Drug Delivery Solutions for Brain Treatment	06/09/23	MT
EXACT Therapeutics and Cordance Medical Announce Strategic Partnership to Revolutionize Drug Delivery to the Brain	06/09/23	CI
Exact Therapeutics Concludes Dose Escalation Under Cancer Therapy Study	07/08/23	MT
EXACT Therapeutics Completes the Dose Escalation Part of ACTIVATE Study	07/08/23	CI
EXACT Therapeutics AS Receives Regulatory Approval to Start the Dose Expansion Part of ACTIVATE Study	31/07/23	CI
EXACT Therapeutics AS Announces Management Changes	09/06/23	CI
EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2022	21/04/23	CI
EXACT THERAPEUTICS AS Presents Encouraging Clinical Case Report Data At Science & Technology Event	28/03/23	CI
Exact Therapeutics Gets UK Clearance to Reopen Phase 1 Acoustic Cluster Therapy Trial	02/02/23	MT
Exact Therapeutics Receives Regulatory Approval to Reopen the Activate Clinical Trial	02/02/23	CI
Norway's Exact Therapeutics Wins NOK16 Million Grant for Cancer Therapy Research; Shares Tumble 24%	22/12/22	MT
Norwegian Research Council Awards EXACT Therapeutics AS Exact-Tx NOK 16 Million to Support the Research of Immunotherapy Responses in Solid Tumours with Acoustic Cluster Therapy	22/12/22	CI
EXACT Therapeutics AS And Tgen Publish Preclinical Data On Acoustic Cluster Therapy Combined With Chemotherapy In A Pancreatic Cancer Model	22/11/22	CI
EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2022	22/09/22	CI
EXACT Therapeutics Appoints Chief Medical Officer	16/09/22	MT
EXACT Therapeutics AS Announces Appointment of Amir Snapir as Chief Medical Officer, Effective 21 September 2022	16/09/22	CI
Norway's Exact Therapeutics Appoints New CFO	31/08/22	MT
EXACT Therapeutics AS Appoints John Edminson as Chief Financial Officer, Effective 1 October 2022	30/08/22	CI
Exact Therapeutics, GE Secure $1.6 Million Norwegian Grant for Ultrasound Imaging, Therapy Project	23/06/22	MT

Chart EXACT Therapeutics

Duration

Period

More charts

Company Profile

Exact Therapeutics AS is a Norway-based clinical-stage biopharmaceutical company, which develops ultrasound-mediated technology platform for targeted therapeutic enhancement Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The Company's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. It is done through harnessing the power of ultrasound in combination with ACT formulation.

Sector

Biotechnology & Medical Research

Calendar

06/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EXACT THERAPEUTICS	-40.83%	21.33M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research